New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 6, 2013
13:58 EDTRHHBYOvarian cancer vaccine yields clinically beneficial responses
A report today at the American Association for Cancer Research meeting in Washington demonstrated a novel two-step immunotherapy approach yielded clinically beneficial responses in patients with advanced ovarian cancer, including one patient who achieved complete remission, according to data from two phase I clinical trials presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10. The treatments were given in conjunction with Roche's (RHHBY) Avastin or bevaccizumab, a drug that controls blood vessel growth. Combining bevacizumab with immunotherapy makes a powerful duo, according to Lana Kandalaft, Pharm.D., M.T.R., Ph.D., assistant professor and director of clinical development and operations at the Ovarian Cancer Research Center in the Perelman School of Medicine at the University of Pennsylvania in Philadelphia.. Currently, the vaccine trial is still open to accrual to test new combinatorial strategies. Reference Link
News For RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
07:51 EDTRHHBYRoche catching up fast to Bristol-Myers in immuno-oncology, says Jefferies
Subscribe for More Information
August 24, 2015
12:01 EDTRHHBYRoche buys nucleic acid purification technology from Lumora
Roche has signed a definitive asset purchase agreement with Lumora for products associated with the patent-protected Heat Elution technology for nucleic acid purification of multiple sample types including challenging formalin-fixed paraffin-embedded tumor samples. Roche plans to explore integrating this technology into its sequencing workflow solution.
August 23, 2015
12:35 EDTRHHBYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
09:38 EDTRHHBYUBS global healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
August 17, 2015
05:14 EDTRHHBYGenentech reports atezolizumab pivotal Phase II study met primary endpoint
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use